Every 8-K that Prestige Consumer Healthcare Inc. (PBH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBH filings page.
Prestige Consumer Healthcare Inc. reports a leadership change in its operations function. On August 10, 2026, Jeffrey Zerillo informed the company of his decision to retire from his role as Senior Vice President, Operations and from all other positions he holds with the company, effective August 14, 2026.
The company’s common stock, par value $0.01 per share, continues to be listed on the New York Stock Exchange under the symbol PBH. The report is signed by Christine Sacco, Chief Financial Officer & Chief Operating Officer.
Prestige Consumer Healthcare reported first-quarter fiscal 2027 revenue of $265.7 million, up 6.5% from $249.5 million a year earlier, with organic sales growth of 3.2%. The Breathe Right acquisition contributed about $5.9 million of revenue, with strong performance in Gastrointestinal and Dermatological categories.
GAAP net income was $29.2 million with diluted EPS of $0.61, down from $0.95, reflecting acquisition, integration and Pillar5 remediation costs and higher interest expense. On a non-GAAP basis, adjusted net income was $46.5 million and adjusted diluted EPS $0.98, up from $0.95. Adjusted EBITDA reached $84.1 million and adjusted EBITDA margin was 31.6%.
Operating cash flow was $70.8 million, and adjusted free cash flow rose to a record $83.7 million. Net debt was about $2.0 billion after funding the Breathe Right and related OTC brands acquisition with a $1.045 billion term loan. Management closed the Breathe Right and LaCorium deals, expects the acquisitions to add nearly 20% to the revenue base, and raised fiscal 2027 guidance to revenue of $1.29–$1.315 billion and adjusted diluted EPS of $4.55–$4.65, with adjusted free cash flow of at least $270 million.
Prestige Consumer Healthcare Inc., through its wholly owned subsidiary Prestige Brands, Inc., issued $400.0 million of 6.250% senior unsecured notes due July 15, 2034. Interest is payable semiannually on January 15 and July 15, beginning January 15, 2027. The notes are guaranteed on a senior unsecured basis by the company and certain existing and future domestic restricted subsidiaries.
The notes are redeemable before and after July 15, 2029 on terms set in the indenture, including optional redemptions with a make-whole premium and the ability to redeem up to 40% using proceeds of certain equity offerings. Upon a defined Change of Control, holders must be offered repurchase at 101% of principal plus accrued interest. The indenture includes customary covenants limiting additional indebtedness, restricted payments, liens, asset sales, mergers and affiliate transactions, subject to exceptions.
Prestige Consumer Healthcare Inc. filed an amended Form 8-K/A to update disclosure around its acquisition of the OTC Wellness Business from Foundation Consumer Brands. The amendment primarily removes an inadvertently included auditor review report and keeps prior 8-K and 8-K/A information otherwise unchanged.
Exhibit 99.2 provides unaudited condensed combined financials for the OTC Wellness Business for the three months ended March 31, 2026. Net sales were $51.7 million versus $50.5 million a year earlier, with net income of $12.6 million compared with $14.8 million.
Prestige Consumer Healthcare Inc. completed its acquisition of Australian skincare company LaCorium Health for approximately $150 million in cash on July 1, 2026, funded with cash on hand and existing credit facilities. LaCorium generates about $40 million in annual revenue and is expected to contribute roughly $12 million in EBITDA once fully integrated.
The company amended its Term Loan Credit Agreement and borrowed $95 million of additional term loans to help finance the acquisition. Prestige also priced a private offering of $400 million in 6.25% senior unsecured notes due 2034, with plans to use the proceeds and cash on hand to redeem all $400 million of existing 5.125% Senior Notes due January 2028. Prestige will report first quarter fiscal 2027 results on August 6, 2026.
Prestige Consumer Healthcare filed an amended report to provide full historical and unaudited pro forma financials for its acquisition of the Breathe Right and related OTC Wellness Business from Foundation Consumer Brands. The purchase price was $1,045.0 million in cash, financed with a matching term loan.
The acquired OTC Wellness Business generated net sales of $196.1 million and net income of $58.2 million for the twelve months ended March 31, 2026. Pro forma combined net sales for that period are $1,284.8 million, with pro forma net income of $180.6 million and diluted EPS of $3.71.
Prestige recorded preliminary identifiable intangible assets of $947.7 million and goodwill of $82.6 million, along with a deferred tax liability of $13.2 million. The filing also details the new Term Loan Credit Agreement and related ABL amendment used to fund the transaction.
Prestige Consumer Healthcare entered a new Term Loan Credit Agreement and completed a major brand acquisition. The company borrowed $1.045 billion in term loans, used to buy the Breathe Right business and certain other brands for a cash purchase price of $1.045 billion. The loan bears interest at Term SOFR plus 2.00% or an alternate base rate and requires quarterly principal payments of 0.25% of outstanding term loans. A second uncommitted term loan draw of up to $95.0 million and an amended ABL Credit Facility with $225 million in aggregate commitments provide additional liquidity, including for the planned LaCorium Health acquisition. Prestige’s press release notes the Breathe Right deal is valued at approximately $900 million net of anticipated tax benefits of $150 million, and that Breathe Right will become its largest brand in a new product category.
Prestige Consumer Healthcare reported fiscal 2026 results and agreed to acquire LaCorium Health for approximately $150 million in cash. Full-year revenue was $1,088.7 million, down 4.3% from the prior year, as limited Clear Eyes supply and shipping disruptions weighed on sales, especially in Eye & Ear Care.
Fiscal 2026 net income was $190.3 million with diluted EPS of $3.91, while non-GAAP adjusted diluted EPS was $4.38. Free cash flow grew to $246.4 million, and the company repurchased 2.3 million shares for about $156 million, ending the year with net debt of roughly $0.9 billion and a 2.6x covenant-defined leverage ratio.
LaCorium generated about $40 million in trailing twelve-month revenue through February 28, 2026 and is expected to deliver roughly $12 million in EBITDA including anticipated synergies. For fiscal 2027, Prestige guides to revenue of $1,100–$1,121 million, organic growth of 1%–3%, adjusted diluted EPS of $4.42–$4.51, and free cash flow of $250 million or more, excluding acquisition impacts.
Prestige Consumer Healthcare Inc. announced a definitive agreement for its subsidiary Prestige Brands, Inc. to acquire the Breathe Right nasal strip brand and certain other over-the-counter consumer health brands from Foundation Consumer Healthcare for $1.045 billion in cash, or approximately $900 million net of anticipated $150 million tax benefits. The assets include Breathe Right, the leading nasal strip brand in the United States with international sales, and brands such as Dimetapp children’s cough and cold relief. The deal is expected to close in the first half of fiscal 2027, subject to customary closing conditions and antitrust clearance, and will be financed with cash on hand and a new Term Loan facility. Management describes the acquisition as margin-accretive and expects it to increase free cash flow and support faster balance-sheet deleveraging.
Prestige Consumer Healthcare Inc. filed a current report to share that it has announced financial results for the fiscal quarter and nine months ended December 31, 2025. The detailed numbers are provided in a separate earnings press release attached as Exhibit 99.1.
The company is also using an investor presentation, attached as Exhibit 99.2, to discuss these results with investors, analysts and others during the fiscal year ending March 31, 2026. Both the press release and presentation are being treated as “furnished,” meaning they are provided for information and are not classified as formally filed financial statements under securities laws.
Prestige Consumer Healthcare (PBH) announced financial results for the fiscal quarter and six months ended September 30, 2025. The company furnished a press release detailing the results as Exhibit 99.1 and an investor presentation as Exhibit 99.2.
Management began using the investor presentation on November 6, 2025 and may use it during the fiscal year ending March 31, 2026. The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, and are not subject to Section 18 liabilities unless specifically stated otherwise.